In a retrospective study, Voorneveld et al1 recently reported a decreased risk of death from any cause and from cancer in statin users belonging to a cohort of colon cancer patients. The beneficial effect correlated with intact bone morphogenetic protein (BMP) signaling and seems to be substantially independent of KRAS mutation status evaluated in cancer specimens. The reported data represent an expanded evidence-based analysis of statin antitumor activity but, despite the strictness of the study, as stated by the authors the results must be considered cautiously.